We serve customers across the pharma value chain
Our vision & execution priorities are focused on needs of our global customers. We champion customer success through continual scientific innovation. Working together with our academic/industry partners, we continually investigate and embrace new technologies to enhance customer value.
We aim to be a market leader in all the 15 to 20 APIs that we currently produce. As a result, most of our products are on continuous manufacturing, with a maximum lead time of 8 to 10 weeks, which, in turn, helps our clients maintain their inventory levels more effectively.
We ensure clients success through our diverse teams of experts with over two decades of industry experience, spanning R&D, regulatory affairs, operations, supply chain, and IT.
For originators and innovators, a cross-functional team led by the R&D head handles inquiries and technical discussions.
In specialty chemicals, a dedicated team manages commercial and technical requirements, ensuring seamless project execution from R&D to commercial manufacturing.
For generic clients, our robust sales and business development team coordinates with production and supply chain teams to meet specific requirements and timelines.
We retain their trust
Chieron is a strategic Partner for CDMO/CMO OpportunitiesAPI/Intermediates for USA/Japan & European Customers. Today, the company has clients across India, Europe, Brazil, Korea, Japan, China, the US, and the Middle East.
With a strong foundation built on backward integration, green chemistry, and regulatory compliance, we aspire to be recognized for our quality and delivery commitments and, eventually, achieve a top-three global position for all our products.
Chieron emphasizes transparency and proactive communication with our clients to mitigate challenges like price fluctuations. Explaining the impact of price fluctuations and maintaining consistent quality and supply has helped us retain their trust and loyalty.
CDMO- Integrated from concept to commercialisation
API
Capability- Proven in 20+ API & still developing
Chieron is on a growth trajectory, with plans to introduce four to seven new API molecules annually, along with new specialty chemicals, while also exploring opportunities in new chemical entities (NCE) with originators.
| Commercial |
|---|
| Product Name |
| AIPAU |
| Benfotiamine |
| Dapagliflozin Propanediol |
| Lacosamide |
| Levetiracetam |
| Linagliptin |
| Loxoprofen Acid |
| Loxoprofen Sodium |
| Olmesartan Medoxomil |
| Oseltamivir |
| Risperidone |
| Rivaroxaban |
| Sitagliptin Phosphate (Chemical) |
| Sitagliptin Phosphate (Enzymatic) |
| Tetracaine Base |
| Tetracaine HCL |
| Vildagliptin |
| Warfarin S Amorphous |
| Warfarin S Clathrate |
| Under Development/Evaluation [API Under Development] | |||
|---|---|---|---|
| Product Name | |||
| Azilsartan | Q2 2024 | Tegoprazan | Q4 2024 |
| Dabigatran Etexilate Mesylate | Q2 2024 | Ticagrelor | Q4 2024 |
| Ezetimibe | Q3 2024 | Tranexamic Acid | Q4 2024 |
| Gabapentine | Q2 2024 | Valsartan | Q2 2024 |
| Losartan Potassium | Q3 2024 | Vonoprazan Fumarate | Q4 2024 |
| Quetiapine Fumarate | Q3 2024 | Zinc Pyrithione | Q4 2024 |
| Rosuvastatin Calcium | Q4 2024 | Zonisamide | Q3 2024 |
| API Under Evalution | ||||
|---|---|---|---|---|
| Product Name | ||||
| Allopurinol | Darolutamide | Evenamide | Lumateperone | Quinfamide |
| Blarcamesine | Elafibranor | Fexuprazan | Mavacamten | Resmetirom |
| Chlorpromazine HCL | Emricasan | Hyaluronic acid | Mirogabalin | Tofisopam |
| Clobenzorex | Epacadostat | Lasmiditan | Omarigliptin | Troriluzole |